GLP-1 receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-09. Anything still debated is marked as such rather than presented as settled.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Affitins (commercial name Nanofitins) are artificial proteins with the ability to selectively bind antigens. They are structurally derived from the DNA binding protein Sac7d, found in Sulfolobus acidocaldarius, a microorganism belonging to the archaeal domain. By randomizing the amino acids on the binding surface of Sac7d and subjecting the resulting protein library to rounds of ribosome display, the affinity can be directed towards various targets, such as peptides, proteins, viruses, and bacteria. Affitins are antibody mimetics and are being developed as an alternative to antibodies as tools in biotechnology. They have also been used as specific inhibitors for various enzymes. Affitins can be utilized in biochemical purification techniques, specifically in affinity chromatography. The ability of Affitins to selectively bind antigens is used to target specific proteins. Scientists have been able to purify human immunoglobulin G (hIgG), bacterial PulD protein, and chicken egg lysozyme using Affitin columns with a high degree of purity. These have the ability to act as specific ligands for the proteins of interest that are needed when the fusion of proteins to polypeptide tags is impossible or carries no advantage, and thus build affinity columns as is the case in the production of biopharmaceuticals. They were immobilized on an agarose matrix and the columns had a high degree of selectivity. In addition to this, antibodies and non-immunoglobin proteins can be purified by using affitins via affinity chromatography.
retort A laboratory apparatus used for the distillation or dry distillation of chemical substances, traditionally consisting of a spherical vessel with a long, downward-pointing neck that conducts the condensed vapors produced by distillation into a separate collection vessel.
== Structure == The gene encoding LepA is known to be the first cistron as part of a bicistron operon. LepA is a polypeptide of 599 amino acids with a molecular weight of 67 kDa. The amino acid sequence of LepA indicates that it is a G protein, which consists of five known domains. The first four domains are strongly related to domains I, II, III, and V of primary elongation factor EF-G. However, the last domain of LepA is unique. This specific domain resides on the C-terminal end of the protein structure. This arrangement of LepA has been observed in the mitochondria of yeast cells to human cells.
Sources: en.wikipedia.org
Reilly suggested to Ding at that time that they should focus the DIT for analysis in the high mass range where other instruments could not compete. However, work published by Ding and Shimadzu over the years following the 2001 meeting were focused on development of square wave driven DIT's in the conventional mass range of commercial instrumentation. During this time Reilly began developing digital waveforms to increase the mass range of quadrupole-based mass spectrometers and ion traps that operate with rectangular waveforms. Over the course of eighteen years, the Reilly group contributed substantially to the development of modern digital waveform technology (DWT), its implementation and characterization, methods of waveform generation, and general theory which includes but is not limited to stability diagrams, the pseudopotential model, and more recently digital quadrupole acceptance. In parallel to Reilly's achievements but also working separately, the Ding group at the Shimadzu Research Lab continued to implement their digital drive technology for a 3D ion trap. Finally, after 18 years Shimadzu unveiled a bench top MALDI square wave driven 3D ion trap mass spectrometer that was designed to work in the higher mass range at the 2019 ASMS conference. The DIT technology has also been developed and implemented in the linear and 3D quadrupole ion traps by many other groups around the world.
On 11 January, two Hezbollah-linked search-and-rescue personnel were killed and an unspecified number of civilians were wounded during an Israeli air raid on the town of Hanine. The IDF said that they killed four militants that infiltrated the Israeli border through Shebaa while an IDF unit was patrolling nearby on 14 January. Five IDF soldiers were wounded. A group calling itself the "Islamic Glory Brigades" later claimed responsibility for the attack and announced that 3 of their members were killed and 2 were able to escape. The same day, two Israeli civilians; a man and his 70-year-old mother, were killed by Hezbollah anti-tank missiles in Kfar Yuval. On 20 January, Brigadier General Sadegh Omidzadeh, an intelligence officer with the IRGC's Quds Force in Syria, along with four other IRGC officers, were reportedly killed in an Israeli airstrike in Damascus. According to the Syrian Observatory for Human Rights, an Israeli missile strike targeted a four-story building in the Mezzeh district. The attack resulted in the death of thirteen individuals, including five Iranians, and the complete destruction of the building where leaders aligned with Iran were having a meeting. The next day, in southern Lebanon, Sky News Arabic reported that Fadi Suleiman, a senior field commander of Hezbollah, survived an Israeli attack near a military checkpoint in Kafra. His bodyguard was killed in the same attack.
High-level waste (HLW) is produced by nuclear reactors and the reprocessing of nuclear fuel. The exact definition of HLW differs internationally. After a nuclear fuel rod serves one fuel cycle and is removed from the core, it is considered HLW. Spent fuel rods contain mostly uranium with fission products and transuranic elements generated in the reactor core. Spent fuel is highly radioactive and often hot. HLW accounts for over 95% of the total radioactivity produced in the process of nuclear electricity generation but it contributes to less than 1% of volume of all radioactive waste produced in the UK. Overall, the 60-year-long nuclear program in the UK up until 2019 produced 2150 m3 of HLW. The radioactive waste from spent fuel rods consists primarily of cesium-137 and strontium-90, but it may also include plutonium, which can be considered transuranic waste. The half-lives of these radioactive elements can differ quite extremely. Some elements, such as cesium-137 and strontium-90 have half-lives of approximately 30 years. Meanwhile, plutonium has a half-life that can stretch to as long as 24,000 years. The amount of HLW worldwide is increasing by about 12,000 tonnes per year. A 1000-megawatt nuclear power plant produces about 27 tonnes of spent nuclear fuel (unreprocessed) every year. For comparison, the amount of ash produced by coal power plants in the United States is estimated at 130,000,000 t per year and fly ash is estimated to release 100 times more radiation than an equivalent nuclear power plant.
Sources: en.wikipedia.org
=== Early applications === In 1903, Ludwig Roselius popularized the use of benzene to decaffeinate coffee. This discovery led to the production of Sanka. This process was later discontinued. Benzene was historically used as a significant component in many consumer products such as liquid wrench, several paint strippers, rubber cements, spot removers, and other products. Manufacture of some of these benzene-containing formulations ceased in about 1950, although Liquid Wrench continued to contain significant amounts of benzene until the late 1970s.
== History of drug delivery == Drug delivery is a process of administering therapeutics to treat human diseases. The first drug delivery system is often dated to the 1950s, when Smith Kline & French Laboratories introduced the Spansule technology. Between 1950s and 1980s, there were four drug release systems developed for oral and transdermal applications: dissolution, diffusion, osmosis, and ion-exchange controlled release. Later in the 1980s, the Lupron Depot technology further advanced the field by offering zero-order and long-term release systems. The intranasal route gained interest towards the end of the 20th century with treating cardiovascular and respiratory diseases. During the late 1980s, William Frey II studied the intranasal route for treating brain diseases. Ever since, it has become a potential route for nose-to-brain delivery.
Cl3C−S−Cl + H2O → Cl−S−C(=O)−Cl + 2 HCl The compound, being bifunctional, has been used for the preparation of several heterocycles including oxathiazol-2-ones, oxathialones, and oxathiazoles. Treatment with formamides gives dithiazolidinediones (also known as dithiasuccinoyl, or DTS). Relevant to amino acid chemistry, ethylthionocarbamates react with chlorocarbonylsulfenyl chloride to give DTS derivatives:
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。